Conditionnement : 500mg
Téléphone : +1 850 650 7790
Synonyms: Gallogen, Elagostasine
| Description | Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity. |
| Targets & IC50 | CK2:40 nM |
| In vitro | METHODS: Human pancreatic cancer cell lines PANC-1, AsPC-1 and MIA PaCA-2 were treated with Ellagic acid (10-1000 µM) for 24-72 h. Cell viability was measured by MTT assay. RESULTS: The proliferation of PANC-1 was inhibited by the addition of 10 µM Ellagic acid in a dose-dependent manner. The proliferation of AsPC-1 was inhibited by the addition of 100 µM Ellagic acid, while the proliferation of MIA PaCA-2 was inhibited only by the addition of 1000 µM Ellagic acid. [1] METHODS: Human lung cancer cells A549 were treated with Ellagic acid (5-20 µM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Ellagic acid treatment significantly down-regulated the phosphorylation of PI3K and Akt in a dose-dependent manner. [2] |
| In vivo | METHODS: To investigate the hepatoprotective effects on alcohol-induced liver disease (ALD), Ellagic acid (50-100 mg/kg suspended in 0.5% CMC-Na) was administered by gavage once daily for four weeks to ICR mice receiving 50% (v/v) alcohol orally daily. RESULTS: Ellagic acid attenuated oxidative stress, inflammatory response, steatosis and gut microbiota dysbiosis in ALD mice. [3] |
| Synonyms | Gallogen, Elagostasine |
| Molecular Weight | 302.19 |
| Formula | C14H6O8 |
| Cas No. | 476-66-4 |
| Smiles | OC1=CC2=C3C(OC(=O)C4=CC(O)=C(O)C(OC2=O)=C34)=C1O |
| Relative Density. | 1.667 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.03 mg/mL (10.03 mM), Sonication is recommended.  | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 0.15 mg/mL (0.5 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
